转载来源：信息量有点大一、核心摘要：全球生物制药格局生变，中国从“仿制药基地” 转向 “创新引擎”全球生物制药行业正处于关键转折点—— 中国生物科技 sector 已从传统仿制药生产，加速融入全球创新生态。摩根士丹利通过多维度分析预测，到 2040 年，中国源创新资产将占美国 FDA 新药批准量的 35%（2024 年仅为 5%），海外市场年收入有望达2200 亿美元，较 2030 年的 340 ...
Source Link转载来源：信息量有点大一、核心摘要：全球生物制药格局生变，中国从“仿制药基地” 转向 “创新引擎”全球生物制药行业正处于关键转折点—— 中国生物科技 sector 已从传统仿制药生产，加速融入全球创新生态。摩根士丹利通过多维度分析预测，到 2040 年，中国源创新资产将占美国 FDA 新药批准量的 35%（2024 年仅为 5%），海外市场年收入有望达2200 亿美元，较 2030 年的 340 ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.